Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/gerona/glab074 http://scihub22266oqcxt.onion/10.1093/gerona/glab074 33711156!7989632!33711156     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Gerontol+A+Biol+Sci+Med+Sci 2021 ; 76 (8): e127-e132 Nephropedia Template TP {{tp|p=33711156|t=2021. Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia |pdf=|usr=}}{{33711156}} gab.com Text Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia JO: J Gerontol A Biol Sci Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=33711156 #FOAvip BACKGROUND: The most susceptible population group to critical and fatal coronavirus disease 2019 (COVID-19) is older adults. In severe acute respiratory syndrome coronavirus 2 infection, the host immune response is thought to play a key role in the pathophysiological effects of lung damage. Therefore, corticosteroid therapy could modulate inflammation-mediated pulmonary injury and thereby reduce progression to severe respiratory failure and death. The aim of this study was to analyze the safety and clinical efficacy of corticosteroid therapy in older adults with severe COVID-19 pneumonia. METHOD: We reviewed the clinical records of confirmed COVID-19 patients aged 75 years or older admitted to our hospital over a 3-month period (March 1-May 31, 2020). A total of 143 patients were included in the study cohort. From 2 April, 2020, in accordance with World Health Organization guidance on COVID-19, our hospital protocol added corticosteroid for COVID-19 treatment. We compared in-hospital mortality among patients with critical COVID-19 who received corticosteroids therapy and those who did not. RESULTS: In total, 88 patients (61.5%) were treated with corticosteroids, and 55 patients (38.4%) were not. Both groups were similar in baseline characteristics. The median age was 85 years (interquartile range: 82-89), and 61.5% (88/143) were male. In-hospital mortality was lower in the corticosteroid group (68.2%) compared with patients in the noncorticosteroid group (81.8%). Treatment with corticosteroids was an independent survival factor (hazard ratio: 0.61; 95% CI: 0.41-0.93; p = .006). CONCLUSIONS: In critically ill older adults with COVID-19 pneumonia, the use of corticosteroid treatment resulted in lower mortality without severe adverse events. Twit Text FOAVip Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia ????J Gerontol A Biol Sci Med Sci http://www.kidney.de/pget.php?&tw=1&pmid=33711156 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33711156 #FOAvip English Wikipedia <ref>{{Cite pmid|33711156}}</ref> Impact of Systemic Corticosteroids on Mortality in Older Adults With Critical COVID-19 Pneumonia #MMPMID33711156 Piniella-Ruiz E; Bellver-Alvarez MT; Mestre-Gomez B; Escolano-Fernandez B; Vinat-Prado S; Cabezas-Olea R; Acedo-Gutierrez MS; Akasbi-Montalvo M; Ryan-Murua P; Bustamante-Fermosel A; Munoz-Rivas N; Santamaria-Garcia C; Pardo-Guimera V; Ulla-Anes M; Franco-Moreno A; Torres-Macho J J Gerontol A Biol Sci Med Sci 2021[Jul]; 76 (8): e127-e132 PMID33711156show ga BACKGROUND: The most susceptible population group to critical and fatal coronavirus disease 2019 (COVID-19) is older adults. In severe acute respiratory syndrome coronavirus 2 infection, the host immune response is thought to play a key role in the pathophysiological effects of lung damage. Therefore, corticosteroid therapy could modulate inflammation-mediated pulmonary injury and thereby reduce progression to severe respiratory failure and death. The aim of this study was to analyze the safety and clinical efficacy of corticosteroid therapy in older adults with severe COVID-19 pneumonia. METHOD: We reviewed the clinical records of confirmed COVID-19 patients aged 75 years or older admitted to our hospital over a 3-month period (March 1-May 31, 2020). A total of 143 patients were included in the study cohort. From 2 April, 2020, in accordance with World Health Organization guidance on COVID-19, our hospital protocol added corticosteroid for COVID-19 treatment. We compared in-hospital mortality among patients with critical COVID-19 who received corticosteroids therapy and those who did not. RESULTS: In total, 88 patients (61.5%) were treated with corticosteroids, and 55 patients (38.4%) were not. Both groups were similar in baseline characteristics. The median age was 85 years (interquartile range: 82-89), and 61.5% (88/143) were male. In-hospital mortality was lower in the corticosteroid group (68.2%) compared with patients in the noncorticosteroid group (81.8%). Treatment with corticosteroids was an independent survival factor (hazard ratio: 0.61; 95% CI: 0.41-0.93; p = .006). CONCLUSIONS: In critically ill older adults with COVID-19 pneumonia, the use of corticosteroid treatment resulted in lower mortality without severe adverse events. |*COVID-19 Drug Treatment[MESH] |*Hospitalization[MESH] |Adrenal Cortex Hormones/*therapeutic use[MESH] |Aged, 80 and over[MESH] |Female[MESH] |Hospital Mortality/*trends[MESH] |Humans[MESH] |Male[MESH] |Respiratory Insufficiency/physiopathology[MESH] |Retrospective Studies[MESH]Impact of Systemic Corticosteroids on Mortality in Older Adults With C(epmc).pdf DeepDyve Pubget Overpricing